RMP-7: ALKS completed Phase II trials

Alkermes Inc. (ALKS), Cambridge, Mass. Product: RMP-7 agent to increase permeability of the blood-brain barrier Indication: Recurrent malignant brain tumor Status: ALKS completed patient enrollment i...